Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 1/20 | 0.41 |
| ▸ | PGR | P06401 | 1/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.41 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.41 |
| ▸ | BCL9 | O00512 | 13/20 | 0.41 |
| ▸ | CTNNB1 | P35222 | 13/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24778021 | 0.86 | GABRD (0.48) | NR3C1PGRSLC6A4KCNH2PDE3B | |
| SCHEMBL21409448 | 0.80 | HSD11B1 (0.42) | NR3C1PGRSLC6A4KCNH2PDE3B | |
| Hydrochloric Acid SCHEMBL23122705 | 0.80 | HSD11B1 (0.41) | NR3C1PGRSLC6A4KCNH2PDE3B | |
| Hydrochloric Acid SCHEMBL30008988 | 0.80 | HSD11B1 (0.41) | NR3C1PGRSLC6A4KCNH2PDE3B | |
| SCHEMBL30984703 | 0.78 | CRBN (0.48) | LMNA | |
| Trifluoroacetic Acid SCHEMBL31696980 | 0.76 | PKM (0.46) | NR3C1PGRSLC6A4KCNH2PDE3B | |
| SCHEMBL28978035 | 0.75 | DDB1 (0.44) | BCL9CTNNB1HSD11B1MEN1KMT2A | |
| SCHEMBL23121698 | 0.73 | HSD11B1 (0.44) | BCL9CTNNB1LMNAHSD11B1MEN1 | |
| SCHEMBL29721053 | 0.72 | LMNA (0.42) | BCL9CTNNB1LMNAHSD11B1KDM4E | |
| SCHEMBL23122011 | 0.72 | GFER (0.44) | BCL9CTNNB1HSD11B1ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220387602-A1 | BIFUNCTIONAL DEGRADERS AND THEIR METHODS OF USE | NOVARTIS AG (CH) | 2022-12-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220387602-A1 | BIFUNCTIONAL DEGRADERS AND THEIR METHODS OF USE | JMJD7, MDM2, IDE | NR3C1 3955/4885PGR 2332/4885SLC6A4 4763/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.